Early results from a phase II study of RRx-001, a novel, triple epigenetic inhibitor, showing resensitization to irinotecan in colorectal cancer Reid, T., Fisher, G., Carter, C., Cho-Phan, C., Kunz, P., Oronsky, B., Fanger, G. R., Caroen, S., Parker, C., Scicinski, J. AMER ASSOC CANCER RESEARCH. 2015

View details for DOI 10.1158/1538-7445.AM2015-CT119

View details for Web of Science ID 000371597100016